Biotech Values

[DewDiligence]

> IDIX – In my AASLD search, I could not find info on [NM283] 48-week (final) data in phase-2b treatment-refractory patients. Perhaps I missed?<

You didn’t miss it—I looked too and it isn’t there.

Evidently, these NM283 data in the treatment-refractory setting data are not going to be presented at AASLD. The reason, I suspect, is that NVS and IDIX are not ready to reveal to the scientific or investor communities what “fix” they have in store to get around the GI side effects at the 800mg dose.